NASDAQ:OBSV - ObsEva Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.80
  • Forecasted Upside: 266.46 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.22
▼ -0.15 (-4.45%)
1 month | 3 months | 12 months
Get New ObsEva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBSV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBSV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.80
▲ +266.46% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ObsEva in the last 3 months. The average price target is $11.80, with a high forecast of $28.00 and a low forecast of $4.00. The average price target represents a 266.46% upside from the last price of $3.22.
Hold
The current consensus among 5 investment analysts is to hold stock in ObsEva. This rating has held steady since December 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2021WedbushReiterated RatingBuy$28.00Low
i
Rating by Liana Moussatos at Wedbush
1/12/2021SVB LeerinkBoost Price TargetOutperform$4.00 ➝ $5.00Low
i
1/4/2021HC WainwrightLower Price TargetBuy$23.00 ➝ $17.00N/A
i
11/9/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
i
10/5/2020HC WainwrightLower Price TargetBuy$36.00 ➝ $23.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/14/2020WedbushReiterated RatingBuy$30.00High
i
Rating by Liana Moussatos at Wedbush
7/7/2020SVB LeerinkLower Price TargetOutperform$7.00 ➝ $5.00High
i
7/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $5.00High
i
7/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00 ➝ $4.00High
i
7/1/2020HC WainwrightReiterated RatingBuy$36.00Low
i
Rating by Ram Selvaraju at HC Wainwright
7/1/2020WedbushReiterated RatingBuy$30.00Low
i
Rating by Liana Moussatos at Wedbush
6/5/2020HC WainwrightReiterated RatingBuy$36.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/5/2020WedbushReiterated RatingBuy$30.00High
i
Rating by Liana Moussatos at Wedbush
3/23/2020WedbushReiterated RatingBuy$40.00 ➝ $34.00Medium
i
Rating by Liana Moussatos at Wedbush
3/23/2020HC WainwrightLower Price TargetBuy$40.00 ➝ $36.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/5/2020WedbushBoost Price TargetOutperform$36.00 ➝ $40.00High
i
Rating by Liana Moussatos at Wedbush
1/21/2020WedbushReiterated RatingBuy$36.00High
i
Rating by Liana Moussatos at Wedbush
1/21/2020HC WainwrightReiterated RatingBuy$40.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/19/2019HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $40.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/10/2019Royal Bank of CanadaBoost Price TargetOutperform$18.00 ➝ $19.00High
i
12/2/2019HC WainwrightReiterated RatingBuy$44.00 ➝ $36.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/8/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$16.00 ➝ $4.00High
i
10/31/2019WedbushReiterated RatingBuy$38.00Medium
i
Rating by Liana Moussatos at Wedbush
10/11/2019WedbushSet Price TargetBuy$38.00Low
i
Rating by Liana Moussatos at Wedbush
9/4/2019HC WainwrightReiterated RatingBuy$44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/11/2019Royal Bank of CanadaReiterated RatingBuyLow
i
7/29/2019Credit Suisse GroupLower Price TargetOutperform$24.00 ➝ $16.00Medium
i
7/18/2019WedbushReiterated RatingOutperform$38.00High
i
Rating by Liana Moussatos at Wedbush
7/8/2019WedbushSet Price TargetBuy$38.00Low
i
Rating by Liana Moussatos at Wedbush
6/19/2019WedbushReiterated RatingBuy$38.00Medium
i
Rating by Liana Moussatos at Wedbush
6/5/2019HC WainwrightSet Price TargetBuy$44.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/28/2019HC WainwrightReiterated RatingBuy$44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/10/2019WedbushSet Price TargetBuy$38.00Medium
i
Rating by Liana Moussatos at Wedbush
5/6/2019HC WainwrightReiterated RatingBuyLow
i
Rating by Ram Selvaraju at HC Wainwright
4/29/2019HC WainwrightReiterated RatingBuyLow
i
Rating by Ram Selvaraju at HC Wainwright
3/7/2019HC WainwrightSet Price TargetBuy$44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/25/2019WedbushSet Price TargetBuy$34.00High
i
Rating by Liana Moussatos at Wedbush
1/23/2019HC WainwrightSet Price TargetBuy$44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/15/2019WedbushSet Price TargetBuy$34.00High
i
Rating by Liana Moussatos at Wedbush
1/4/2019HC WainwrightSet Price TargetBuy$44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/11/2018WedbushReiterated RatingBuy$34.00Low
i
Rating by Liana Moussatos at Wedbush
12/10/2018HC WainwrightReiterated RatingBuy$44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/15/2018HC WainwrightSet Price TargetBuy$44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/3/2018WedbushSet Price TargetBuy$34.00High
i
Rating by Liana Moussatos at Wedbush
9/13/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$29.00Low
i
8/29/2018HC WainwrightSet Price TargetBuy$44.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/15/2018SVB LeerinkInitiated CoverageOutperform$25.00Low
i
Rating by A. Fadia at SVB Leerink LLC
8/8/2018HC WainwrightSet Price TargetBuy$44.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/6/2018WedbushInitiated CoverageOutperform$34.00High
i
Rating by L. Moussatos at Wedbush
7/25/2018HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
7/19/2018Credit Suisse GroupInitiated CoverageOutperform$24.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
7/16/2018HC WainwrightSet Price TargetBuy$30.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/18/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$23.00 ➝ $31.00High
i
6/12/2018BMO Capital MarketsInitiated CoverageOutperform$23.00High
i
6/11/2018HC WainwrightSet Price TargetBuy$28.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/29/2018HC WainwrightReiterated RatingBuy$28.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/9/2018HC WainwrightReiterated RatingBuy$27.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/27/2018BMO Capital MarketsReiterated RatingBuy$24.00High
i
2/27/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.00High
i
2/27/2018Credit Suisse GroupReiterated RatingOutperform ➝ Buy$16.00 ➝ $18.00Low
i
2/5/2018HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/4/2018HC WainwrightSet Price TargetBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/14/2017HC WainwrightSet Price TargetBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/4/2017BMO Capital MarketsInitiated CoverageOutperform$20.00Low
i
11/29/2017HC WainwrightSet Price TargetBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/8/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
11/2/2017Royal Bank of CanadaReiterated RatingBuy$22.00N/A
i
10/30/2017HC WainwrightSet Price TargetBuy$25.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/11/2017HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $25.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/9/2017Credit Suisse GroupInitiated CoverageOutperform$27.00 ➝ $16.00N/A
i
10/4/2017HC WainwrightReiterated RatingBuy$27.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$22.00Low
i
9/8/2017HC WainwrightReiterated RatingBuy$27.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/16/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$18.00High
i
Rating by J. Gerberry at SVB Leerink LLC
8/16/2017HC WainwrightSet Price TargetBuy$27.00Low
i
Rating by Ram Selvaraju at HC Wainwright
6/29/2017HC WainwrightInitiated CoverageBuy ➝ Buy$27.00High
i
4/18/2017Credit Suisse GroupReiterated RatingOutperform$27.00Low
i
2/21/2017SVB LeerinkInitiated CoverageOutperform$21.00N/A
i
Rating by J. Gerberry at SVB Leerink LLC
2/21/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$27.00N/A
i
2/21/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$21.00N/A
i
(Data available from 3/7/2016 forward)
ObsEva logo
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $3.22
$2.85
$3.48

50 Day Range

MA: $3.99
$2.52
$5.05

52 Week Range

Now: $3.22
$1.63
$6.30

Volume

3,334,881 shs

Average Volume

8,352,549 shs

Market Capitalization

$154.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?

The following Wall Street sell-side analysts have issued reports on ObsEva in the last year: BMO Capital Markets, HC Wainwright, JPMorgan Chase & Co., SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for OBSV.

What is the current price target for ObsEva?

5 Wall Street analysts have set twelve-month price targets for ObsEva in the last year. Their average twelve-month price target is $11.80, suggesting a possible upside of 266.5%. Wedbush has the highest price target set, predicting OBSV will reach $28.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $4.00 for ObsEva in the next year.
View the latest price targets for OBSV.

What is the current consensus analyst rating for ObsEva?

ObsEva currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OBSV, but not buy more shares or sell existing shares.
View the latest ratings for OBSV.

What other companies compete with ObsEva?

How do I contact ObsEva's investor relations team?

ObsEva's physical mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company's listed phone number is 41-22-552-3840 and its investor relations email address is [email protected] The official website for ObsEva is www.obseva.com.